Zimmer Biomet’s (ZBH) “Buy” Rating Reiterated at Argus
Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Argus in a research note issued to investors on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s target price suggests a potential upside of 27.64% from the company’s previous […]
22 Oct 15:30 · The Markets Daily
Centrus Energy’s (LEU) Buy Rating Reiterated at HC Wainwright
Centrus Energy (NYSE:LEU – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $300.00 price target on the stock. HC Wainwright‘s target price points to a potential upside of 173.07% from the stock’s current […]
21 Oct 08:30 · The Cerbat Gem
Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $361.00 price target on the stock. Other research analysts have also recently issued reports about the stock. Citigroup upped their price objective on shares of Krystal Biotech from […]
18 Oct 06:18 · The Markets Daily
Belite Bio’s (BLTE) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research report sent to investors on Thursday morning, Marketbeat reports. The firm currently has a $245.00 target price on the stock. BLTE has been the subject of several other research reports. Benchmark reissued a “buy” rating on shares […]
18 Oct 05:24 · The Markets Daily
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $1,201.00 price target on the stock. Other equities analysts have also recently issued research reports about the company. BTIG Research upped their price target on Praxis […]
18 Oct 05:13 · The Markets Daily
Biomea Fusion’s (BMEA) “Buy” Rating Reiterated at HC Wainwright
Biomea Fusion (NASDAQ:BMEA – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 217.46% from […]
14 Oct 08:07 · The Cerbat Gem
last updated on 22 Oct 18:30